^
    Back
    Association details:
    Biomarker:TTF1 negative
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Regimen: (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer

    Published date:
    10/19/2023
    Excerpt:
    Long-term efficacy was generally observed in TTF-1-negative patients treated with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) (median PFS 22.5 months, median OS not reached).
    DOI:
    10.21037/tlcr-23-331